122 related articles for article (PubMed ID: 21476922)
1. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?
Lonardo A; Bellentani S; Ratziu V; Loria P
Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):279-89. PubMed ID: 21476922
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Sanyal AJ; Campbell-Sargent C; Mirshahi F; Rizzo WB; Contos MJ; Sterling RK; Luketic VA; Shiffman ML; Clore JN
Gastroenterology; 2001 Apr; 120(5):1183-92. PubMed ID: 11266382
[TBL] [Abstract][Full Text] [Related]
3. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
[TBL] [Abstract][Full Text] [Related]
4. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH
Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis.
Idilman R; Mizrak D; Corapcioglu D; Bektas M; Doganay B; Sayki M; Coban S; Erden E; Soykan I; Emral R; Uysal AR; Ozden A
Aliment Pharmacol Ther; 2008 Jul; 28(2):200-8. PubMed ID: 18445142
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
Promrat K; Lutchman G; Uwaifo GI; Freedman RJ; Soza A; Heller T; Doo E; Ghany M; Premkumar A; Park Y; Liang TJ; Yanovski JA; Kleiner DE; Hoofnagle JH
Hepatology; 2004 Jan; 39(1):188-96. PubMed ID: 14752837
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of nonalcoholic steatohepatitis (NASH).
Ma X; Li Z
Chin J Dig Dis; 2006; 7(1):7-11. PubMed ID: 16412031
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues.
Ratziu V; Caldwell S; Neuschwander-Tetri BA
Hepatology; 2010 Dec; 52(6):2206-15. PubMed ID: 21105109
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic steatohepatitis in children.
Nanda K
Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
[TBL] [Abstract][Full Text] [Related]
10. The treatment of NAFLD.
Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C
Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594
[TBL] [Abstract][Full Text] [Related]
11. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell SH; Hespenheide EE; Redick JA; Iezzoni JC; Battle EH; Sheppard BL
Am J Gastroenterol; 2001 Feb; 96(2):519-25. PubMed ID: 11232700
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
Bugianesi E; Gentilcore E; Manini R; Natale S; Vanni E; Villanova N; David E; Rizzetto M; Marchesini G
Am J Gastroenterol; 2005 May; 100(5):1082-90. PubMed ID: 15842582
[TBL] [Abstract][Full Text] [Related]
15. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis.
Caldwell SH; Patrie JT; Brunt EM; Redick JA; Davis CA; Park SH; Neuschwander-Tetri BA
Hepatology; 2007 Oct; 46(4):1101-7. PubMed ID: 17661371
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
Tiniakos DG
Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):643-50. PubMed ID: 19478676
[TBL] [Abstract][Full Text] [Related]
17. Commonly used animal models of non-alcoholic steatohepatitis.
Fan JG; Qiao L
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):233-40. PubMed ID: 19502161
[TBL] [Abstract][Full Text] [Related]
18. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.
Boza C; Riquelme A; Ibañez L; Duarte I; Norero E; Viviani P; Soza A; Fernandez JI; Raddatz A; Guzman S; Arrese M
Obes Surg; 2005 Sep; 15(8):1148-53. PubMed ID: 16197788
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease in severely obese subjects.
Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
